Legal Representation
Attorney
Monica Riva Talley
USPTO Deadlines
Next Deadline
1779 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-06-18)
Due Date
June 18, 2030
Grace Period Ends
December 18, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
42 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 18, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jun 18, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| May 10, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| May 10, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Apr 26, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 9, 2024 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Jan 4, 2024 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Jan 4, 2024 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Jan 4, 2024 | CNFR | W | SU - FINAL REFUSAL - WRITTEN | Loading... |
| Jan 4, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 4, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 3, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 25, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 25, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 25, 2023 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Sep 23, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Sep 23, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Sep 19, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Sep 19, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Apr 17, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Apr 17, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 17, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jan 31, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 27, 2023 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jan 27, 2023 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 27, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 19, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 17, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Oct 17, 2022 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Oct 17, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 19, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 15, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 15, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Apr 15, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 19, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 24, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 24, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 4, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 16, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 14, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 2, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 30, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), frontotemporal dementia, and cognitive impairment of aging; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, chronic neuropathic pain and peripheral neuropathy; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, agitation in AD, and disinhibition in dementia; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, Obsessive Compulsive Disorder (OCD) and Generalized Anxiety Disorder (GAD); pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia
First Use Anywhere:
20230700
First Use in Commerce:
20230700
Classification
International Classes
005